Compare Crispr Therapeutics AG (CRSP) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Union Pacific Corporation — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Union Pacific Corporation trades at $278.34 (market cap $165.27B). The key difference: Union Pacific Corporation is far larger — about 33.9× Crispr Therapeutics AG's market cap, and Union Pacific Corporation pays a 2.04% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Union Pacific Corporation for 105 Days on average.
| CRSP | UNP | |
|---|---|---|
Market Cap | $4.88B | $165.27B |
Volume | 2,861,747 | 1,474,117 |
Sector | Health | Industrials |
52-Week High | $73.97 | $310.62 |
52-Week Low | $44.34 | $216.37 |
Typical Hold Time | 77 Days | 105 Days |
Enterprise Value | $3.30B | $194.33B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
Union Pacific (UNP) trades at $278.20, up 1.28% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations, and the company maintains robust profitability with a 28.85% net margin and 39.7% ROE. Positive sentiment is driven by volume growth, a pending Norfolk Southern merger, and dividend reliability, though merger uncertainty and fuel costs pose risks.
Outlook is positive given earnings momentum and strategic initiatives, but investors face risks from merger execution and economic cyclicality. The stock offers value with a consensus price target of $332.10, implying significant upside, supported by stable cash flows and a solid dividend track record.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
